Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

283
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
283
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

The efficacy of the remote monitoring system following transcatheter aortic valve replacement.

Cardiovascular revascularization medicine : including molecular interventions·2025
Same author

Acquired pulmonary vein stenosis resulting in haemoptysis: a case series.

European heart journal. Case reports·2021
Same author

Sex-Related Differences in the Outcomes of Endovascular Interventions for Chronic Limb-Threatening Ischemia: Results from the LIBERTY 360 Study.

Vascular health and risk management·2020
Same author

Delayed occurrence of radial artery pseudoaneurysm following transradial percutaneous coronary intervention.

Journal of cardiology cases·2018

Related Experiment Video

Updated: Apr 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

Orbital atherectomy: device evolution and clinical data.

Cezar S Staniloae1, Ravikiran Korabathina

  • 1Heart and Vascular Institute, New York University Medical Center, New York, New York, USA. cezar.staniloae@nyumc.org.

The Journal of Invasive Cardiology
|May 6, 2014
PubMed
Summary

The DiamondBack 360° Peripheral Orbital Atherectomy System effectively treats severely calcified plaque. This review covers its history, mechanism, clinical data, and future uses in peripheral artery disease.

More Related Videos

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.3K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

21.6K

Related Experiment Videos

Last Updated: Apr 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.3K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

21.6K

Area of Science:

  • Vascular surgery
  • Interventional cardiology
  • Medical device technology

Background:

  • Atherectomy devices are crucial for treating peripheral artery disease.
  • Severely calcified lesions pose a significant challenge for current treatment options.
  • The DiamondBack 360° Peripheral Orbital Atherectomy System was developed to address this unmet need.

Purpose of the Study:

  • To provide a comprehensive review of the DiamondBack 360° Peripheral Orbital Atherectomy System.
  • To discuss its historical development and evolution.
  • To examine its mechanism of action, clinical efficacy, and future potential.

Main Methods:

  • Literature review of historical data, device evolution, and clinical studies.
  • Analysis of the mechanism of action for peripheral orbital atherectomy.
  • Synthesis of published clinical data regarding safety and effectiveness.

Main Results:

  • The DiamondBack 360° system utilizes orbital abrasion to debulk calcified plaque.
  • Clinical studies demonstrate its effectiveness in treating complex, calcified peripheral lesions.
  • The device has shown a favorable safety profile in various patient populations.

Conclusions:

  • The DiamondBack 360° Peripheral Orbital Atherectomy System is a valuable tool for managing severely calcified peripheral artery disease.
  • Its unique mechanism allows for effective plaque modification where other devices may fail.
  • Continued research and clinical application will further define its role in interventional cardiology.